Sagard Capital's $170M Buy To Take IntegraMed Private
The $14.05-per-share cash offer represents a 24 percent premium over IntegraMed's Friday close, and a 46 percent premium on the company's average closing price over the past year. The deal is not subject to financing, according to IntegraMed.
Pending shareholder and regulatory approval, the transaction is expected to close by the end of...
To view the full article, register now.